These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 34076247)
1. Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy - current and future perspectives. Prakoso D; Tate M; Blasio MJ; Ritchie RH Clin Sci (Lond); 2021 Jun; 135(11):1369-1387. PubMed ID: 34076247 [TBL] [Abstract][Full Text] [Related]
2. Gene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes. Prakoso D; De Blasio MJ; Tate M; Kiriazis H; Donner DG; Qian H; Nash D; Deo M; Weeks KL; Parry LJ; Gregorevic P; McMullen JR; Ritchie RH Am J Physiol Heart Circ Physiol; 2020 Apr; 318(4):H840-H852. PubMed ID: 32142359 [TBL] [Abstract][Full Text] [Related]
3. Nerve growth factor gene therapy using adeno-associated viral vectors prevents cardiomyopathy in type 1 diabetic mice. Meloni M; Descamps B; Caporali A; Zentilin L; Floris I; Giacca M; Emanueli C Diabetes; 2012 Jan; 61(1):229-40. PubMed ID: 22187379 [TBL] [Abstract][Full Text] [Related]
4. A gene therapy targeting medium-chain acyl-CoA dehydrogenase (MCAD) did not protect against diabetes-induced cardiac pathology. Weeks KL; Kiriazis H; Wadley GD; Masterman EI; Sergienko NM; Raaijmakers AJA; Trewin AJ; Harmawan CA; Yildiz GS; Liu Y; Drew BG; Gregorevic P; Delbridge LMD; McMullen JR; Bernardo BC J Mol Med (Berl); 2024 Jan; 102(1):95-111. PubMed ID: 37987775 [TBL] [Abstract][Full Text] [Related]
5. MiR-21 protected against diabetic cardiomyopathy induced diastolic dysfunction by targeting gelsolin. Dai B; Li H; Fan J; Zhao Y; Yin Z; Nie X; Wang DW; Chen C Cardiovasc Diabetol; 2018 Sep; 17(1):123. PubMed ID: 30180843 [TBL] [Abstract][Full Text] [Related]
6. Phosphoinositide 3-kinase (p110α) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction. Prakoso D; De Blasio MJ; Qin C; Rosli S; Kiriazis H; Qian H; Du XJ; Weeks KL; Gregorevic P; McMullen JR; Ritchie RH Clin Sci (Lond); 2017 Jun; 131(12):1345-1360. PubMed ID: 28487469 [TBL] [Abstract][Full Text] [Related]
7. Versatility of AAV vectors for retinal gene transfer. Surace EM; Auricchio A Vision Res; 2008 Feb; 48(3):353-9. PubMed ID: 17923143 [TBL] [Abstract][Full Text] [Related]
9. The state of the art of adeno-associated virus-based vectors in gene therapy. Coura Rdos S; Nardi NB Virol J; 2007 Oct; 4():99. PubMed ID: 17939872 [TBL] [Abstract][Full Text] [Related]
10. Vectrology of adeno-associated viruses (AAV). Skubis-Zegadło J; Stachurska A; Małecki M Med Wieku Rozwoj; 2013; 17(3):202-6. PubMed ID: 24296444 [TBL] [Abstract][Full Text] [Related]
12. Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications. Schön C; Biel M; Michalakis S Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):343-52. PubMed ID: 25615882 [TBL] [Abstract][Full Text] [Related]
13. AAV6 Vector Production and Purification for Muscle Gene Therapy. Halbert CL; Allen JM; Chamberlain JS Methods Mol Biol; 2018; 1687():257-266. PubMed ID: 29067669 [TBL] [Abstract][Full Text] [Related]
14. Autophagy determines efficiency of liver-directed gene therapy with adeno-associated viral vectors. Hösel M; Huber A; Bohlen S; Lucifora J; Ronzitti G; Puzzo F; Boisgerault F; Hacker UT; Kwanten WJ; Klöting N; Blüher M; Gluschko A; Schramm M; Utermöhlen O; Bloch W; Mingozzi F; Krut O; Büning H Hepatology; 2017 Jul; 66(1):252-265. PubMed ID: 28318036 [TBL] [Abstract][Full Text] [Related]
15. Cancer gene therapy using adeno-associated virus vectors. Park K; Kim WJ; Cho YH; Lee YI; Lee H; Jeong S; Cho ES; Chang SI; Moon SK; Kang BS; Kim YJ; Cho SH Front Biosci; 2008 Jan; 13():2653-9. PubMed ID: 17981740 [TBL] [Abstract][Full Text] [Related]
16. Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling. Katare R; Caporali A; Zentilin L; Avolio E; Sala-Newby G; Oikawa A; Cesselli D; Beltrami AP; Giacca M; Emanueli C; Madeddu P Circ Res; 2011 May; 108(10):1238-51. PubMed ID: 21474815 [TBL] [Abstract][Full Text] [Related]
17. Engineered nanoparticles promote cardiac tropism of AAV vectors. Switala L; Di L; Gao H; Asase C; Klos M; Rengasamy P; Fedyukina D; Maiseyeu A J Nanobiotechnology; 2024 May; 22(1):223. PubMed ID: 38702815 [TBL] [Abstract][Full Text] [Related]
18. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Grimm D; Kay MA Curr Gene Ther; 2003 Aug; 3(4):281-304. PubMed ID: 12871018 [TBL] [Abstract][Full Text] [Related]
19. Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of Crigler-Najjar Syndrome Type I. Bočkor L; Bortolussi G; Iaconcig A; Chiaruttini G; Tiribelli C; Giacca M; Benvenuti F; Zentilin L; Muro AF Gene Ther; 2017 Oct; 24(10):649-660. PubMed ID: 28805798 [TBL] [Abstract][Full Text] [Related]